Platforms
Our modular ADC platforms are generating potential first and best in class assets, including novel proprietary payloads, linker and drug conjugation and improved targeting. This includes clinically validated MOAs, dual payloads, and tumor specific release. These platforms are enabling us to efficiently engineer ADCs that tackle cancers that current therapies cannot, with a multiplier effect of technology platforms delivering solutions beyond today’s therapeutic boundaries.
We are open to exploring strategic collaborations, licensing opportunities, and co-development partnerships across our platforms and proprietary programs.
ADC Technology Powerhouse Generating First/Best-in-Class Assets
Novel Payloads Antifolate ADCs
A first-in-class antifolate payload leveraging a clinically validated mechanism of action not previously used in targeted therapy, designed to overcome resistance to existing ADCs and expand treatment options for patients facing difficult-to-treat cancers.
ByonBoosT™: Phosphonate ADCs
A first-in-class immunostimulatory phosphonate payload designed to address a critical need for patients who do not respond to immunotherapy, powering tumor-selective activation of γδ T cells through MHC-independent recognition of cancer cells.
Dual Payloads
A proprietary dual payload platform combining clinically validated conjugation and linker technologies, with unprecedented synergistic payload combinations and high compatibility with existing linker-drugs.
ByonGuard™: Masked Therapeutics
A best-in-class steric masking platform providing a universal solution to reduce off-tumor toxicity, designed to improve the therapeutic index of antibody-based therapies with no bespoke peptides needed.
Pipeline
Our diverse pipeline of proprietary next-generation ADCs reflects our expertise in research, lead identification, preclinical/clinical development, process development and manufacturing.
Key Technologies
Byondis has a suite of proprietary technologies available to generate promising clinical candidates. This includes next generation ADCs containing our proprietary duocarmazine linker-drug (LD) technology ByonZine®.
